Review of the twelfth West Coast retrovirus meeting by Barry, Sheila M et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Retrovirology
Open Access Review
Review of the twelfth West Coast retrovirus meeting
Sheila M Barry†1,2, Marta Melar†1,2, Philippe Gallay3 and Thomas J Hope*1
Address: 1Department of Cell and Molecular Biology, College of Medicine, Northwestern University, Chicago, IL 60611, USA, 2Department of 
Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA and 3The Scripps Research 
Institute, La Jolla, CA 92037, USA
Email: Sheila M Barry - s-barry@northwestern.edu; Marta Melar - m-melar@northwestern.edu; Philippe Gallay - gallay@scripps.edu; 
Thomas J Hope* - thope@northwestern.edu
* Corresponding author    †Equal contributors
Abstract
Every year the Cancer Research Institute from University of California at Irvine organizes the West
Coast Retrovirus Meeting where participants have a chance to discuss the latest progress in
understanding the pathology of retroviruses. The 12th meeting was held at the Hyatt Regency Suites
in Palm Springs, California from October 6th to October 9th 2005, with the major focus on human
immunodeficiency virus (HIV) pathogenesis. Philippe Gallay from The Scripps Research Institute
and Thomas J. Hope from Northwestern University organized the meeting, which covered all the
steps involved in the lifecycle of retroviruses with an emphasis on virus:host interactions. The trend
in research appeared to be on the restriction of viral infection, both by the endogenous, cellular
restriction factors, as well as by the potential antimicrobial compounds of known or unknown
mechanisms. Additionally, new stories on the inevitable feedback from the host immune system
were presented as well. HIV still represents a challenge that an army of motivated people has been
working on for over 20 years. And yet, the field has not reached the plateau in knowledge nor
enthusiasm, which was proven again in October 2005 in Palm Springs.
Review
Viral Entry
John Young of the Salk Institute began this session by
describing work his lab has recently completed in under-
standing cellular requirements for replication of Murine
Leukemia Virus (MLV) [1]. Through use of chemically
mutagenized CHO cells, they identified five clones that
became resistant to MLV infection. Additional studies
revealed this restriction was specific to the MLV core. After
confirming the virus was blocked prior to integration, the
clones were separated into two phenotypes, those which
blocked reverse transcription early and those which
allowed reverse transcription and nuclear entry, but pre-
vented viral integration. Young and colleagues are cur-
rently identifying cellular factors involved in the latter
phenotype. While the exact identities of these cellular fac-
tors were not revealed, Young shared that they believe one
is an enzyme and the other a putative transcription factor.
Pankaj Kumar from Lorraine Albritton's lab at the Univer-
sity of Tennessee continued this theme by examining cel-
lular factors involved in Moloney MLV entry. Previous
work found that the exposure of MLV to proteases
enhanced the viral infectivity and certain cell lines, includ-
ing XC cells, innately possessed proteases that could facil-
itate MLV infection. The group decided to focus on
cathepsins, since expression of these cellular proteases is
induced under these conditions. They found a broad spec-
trum cathepsin inhibitor as well as a cathepsin B-specific
inhibitor reduced Moloney MLV infectivity. Additionally,
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treatment of viral particles with cathepsin B resulted in
cleavage of the surface glycoprotein (SU). They postulate
Moloney MLV encounters cathepsin B within early lyso-
somes and the ensuing cleavage of SU facilitates fusion
and entry steps.
Two talks turned attention to the involvement of HIV
envelope glycoprotein gp41 in early steps of viral infec-
tion. In work previously published by his lab, John Day of
the University of California San Diego and others deter-
mined the membrane proximal tyrosine based sorting sig-
nal of gp41, Y712xxL, was important in viral entry and
infectivity and was involved in virion incorporation of the
envelope glycoprotein (Env) only in some cell lines [2].
They hypothesized this enhancement of viral infectivity
resulted from the virus using adaptor protein complexes
to traffic Env to specific cellular membranes. Gp41 has
few motifs that are known to interact with adaptor pro-
teins (AP); Y712xxL interacts with AP-2, while the C-ter-
minal double leucine motif (LL855/856) binds to AP-1.
Thus, both signals were evaluated for their ability to affect
intracellular localization and viral infectivity. In studies
using CXCR4 tropic HIV-1, LL855/856 was found to have
no effect on viral infectivity or entry, a sharp contrast from
the observed viral dependence on Y712xxL. However, no
difference was observed in intracellular localization of
either mutant compared to wildtype. This suggests the Env
sorting signals may not be involved in targeting viral mor-
phogenesis to specific cellular membranes. Interestingly,
when these signals were evaluated with CCR5 tropic HIV-
1, neither the LL855/86 nor the Y712xxxL sorting signal
had any effect on viral infectivity. This observation indi-
cated the significance of the tyrosine-sorting signal in viral
infectivity is dependent on the tropism of the HIV Env
ectodomain.
Michael Kay from the University of Utah presented his
lab's efforts in understanding the ineffectiveness of vac-
cine development against the N trimer of gp41. Following
gp120 binding to coreceptor, gp41 undergoes conforma-
tional changes, from a pre-hairpin state where both N and
C peptides are exposed, to the formation of a six-helix
bundle, where a trimer of N peptides (N trimer) is sur-
rounded by three C peptides. Within this N-trimer is a
highly conserved pocket which has become the target of
most vaccine development. Unfortunately, little progress
has been made in creating an effective anti N trimer vac-
cine. Kay and collaborators considered a potential obsta-
cle to vaccine development was the accessibility of the
region to bulky inhibiting proteins. To evaluate this pos-
sibility, this group used a C-peptide inhibitor that was
attached via a flexible linker to several cargo proteins of
various sizes. They found the potency of this inhibitor
decreased with increasing cargo protein size. Increasing
the length of the flexible linker region could restore
potency [3]. This suggests a severe steric block in gp41 to
neutralizing antibodies.
The session ended with a talk by Marta Melar from Tho-
mas Hope's lab at Northwestern University on coreceptor
dependent signaling during HIV entry. By measuring
changes in intracellular calcium (Ca2+) levels as a marker
for signaling through coreceptor, Melar observed that sig-
naling was coreceptor specific, responsive to both mono-
meric and virion bound gp120, and dependent on CD4.
The fluorescent microscopic technique employed in these
studies allowed Melar to quantate the number of virions
bound to Ca2+- fluxing cells. An average of four virions
was determined to be sufficient for Ca2+ mobilization in
primary unstimulated CD4+ T cells.
Vif, Vpr and Nef
Several interesting talks emphasized the ability of these
accessory HIV proteins to evade the host immune system
in order to make a perfect niche for viral replication in the
hostile target cells. The stories on Vif protein focused on
its ability to protect the virions from incorporation of the
cellular apolipoprotein B mRNA-editing enzyme-catalytic
polypeptide-like-3G (APOBEC-3G or A3G) [4]. A3G has
cytidine deamination activity and can use newly reverse
transcribed viral genome as a substrate, leading to the loss
of viral fitness through introduction of G-to-A hypermuta-
tions in the plus strand of the cDNA
Jason Kreisberg, a graduate student from Warner Greene's
lab from University of California at San Francisco, pre-
sented the ongoing work in the lab regarding the mecha-
nism of A3G dependant HIV restriction in secondary
lymphoid organs. This work is the continuation of already
published data [5] on two existing forms of A3G, high and
low molecular weight A3G, where only a low molecular
weight form exhibits enzymatic activity. RNase treatment
was shown to facilitate the switch from the high into low
molecular weight form. Kreisberg emphasized the correla-
tion between the presence of the A3G molecular weight
form and permissiveness of the cell type to infection. They
found resting peripheral CD4+ T cells that are not permis-
sive for infection express the enzymatically active version
of A3G. However, when isolated from tonsils and cultured
in conditioned media, this cell type becomes permissive
to HIV infection. Cytokines, specifically IL-2 and IL-15,
may have a role in this in vivo switch from low to high
molecular weight A3G. These data could shed some light
on the role of the target cell A3G opposing the well-estab-
lished mutagenizing role of A3G on the HIV genome in
the producer cells. Since only high molecular weight A3G
is incorporated into ∆Vif virions, it was not known how
A3G gains its activity in the target cells. The virally
encoded enzyme RNaseH may be doing the virus a contra-Retrovirology 2005, 2:72 http://www.retrovirology.com/content/2/1/72
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favor, by functioning as the facilitator of A3G cytidine
deaminase activation.
The session continued with another keynote lecture given
by Nathaniel Landau from the Salk Institute for Biological
Studies from San Diego. This talk was focused on the spe-
cies-specificity of the Vif:A3G interaction. The ability of
Vif to block the antiviral activity of A3G is species-specific
[6], where the positive charge of single Asp in the position
128 within human A3G is responsible for recognition of
HIV Vif and its interaction. From mutational analyses,
Landau and his collaborators found that out of two active
sites within APOBEC family of enzymes, the first active
site (AS1) plays a role in encapsidation of the enzyme into
the ∆Vif virions, where AS2 is responsible for deamination
of the substrate, the negative DNA single strands in a
newly synthesized viral genome. As well, the group found
a graded deamination frequency, from low at the 5'-end to
higher towards the 3'-end, most likely a phenomenon
affected by the mechanism of the reverse transcription
reaction and the availability of negative strand cDNA to
the A3G-induced mutation.
The following talk from Michael Emerman’s group at the
Fred Hutchinson Cancer Research Center continued the
discussion on different aspects of antiviral properties of
APOBEC enzymes.  Shari Kaiser addressed the question if
the uracil DNA glycosylase 2 (UNG2) is involved in the
antiviral effects of A3G.  Previously, this enzyme was pos-
tulated to work one step downstream of A3G, enabling G-
to-A hypermutations to occur.   However, Kaiser found
that virus replication in either target or producer cells was
not affected as compared to the positive control in either
ung-/- cell line or after the UNG2 inhibitor treatment in
the producer cells.  This implied UNG2 was dispensable
for the fitness of the virus contrasting with a recent publi-
cation [7].
Another focus on host:virus interaction came from More-
house School of Medicine in Atlanta, where Michael Pow-
ell's group works on HIV infectivity enhancement through
the direct Nef and CypA interaction. This work was based
on the hypothesis that CypA acts as a linker between HIV
Nef and the viral core, interacting with Nef at its N-termi-
nus and the core through its C-terminus. They speculate
this interaction between Nef and CypA can facilitate the
uncoating process in the target cells, since induction of
natural endogenous reverse transcription (NERT) in intact
virions could overcome the lack of either protein. They
also showed a Nef:CypA fusion protein, which efficiently
got incorporated into virions, restored infectivity of ∆Nef
virions. Interestingly, the group also suggested that the
ability of SIV Nef to bind core directly might mask the
restriction effect of cellular restriction factor TRIM5α that
is known to interact with viral core, since HIV virions
expressing SIV Nef were able to bypass the restriction
point of simian TRIM5α and replicate in simian MAGI
cells. That was also the case with NERT induced wild type
HIV in simian MAGI cells.
The mechanism of MHC class II invariant chain (Ii) up-
regulation was another Nef function discussed during this
session. Richard Mitchell from University of California at
San Diego presented work on the importance of the di-
leucine sorting motif E160xxxLL found at the C-terminus
of HIV Nef and its potential role in providing a sorting
endocytic signal for down-regulation of the surface
expression of CD4, coreceptors CXCR4 and CCR5, MHC I
and II and up-regulation of MHC II-Ii complexes at the
cell surface. By using yeast three-hybrid system and GST-
pulldown assays, the group found that residues E160 and
LL were important for up-regulation of the surface Ii
expression. This is another report explaining the role of
this accessory HIV protein in enhancing the infectivity of
the virus, by altering the immune response of the host.
Uncoating and budding
The next panel began with two keynote lectures, both
focusing on the issue of viral restriction in different hosts.
Jaquelin Dudley from University of Austin, Texas, intro-
duced us to the world of mouse resistance to multiple
pathogens. Her group observed that certain strains of
inbred mice carry an endogenous mouse mammary
tumor virus (MMTV) that is replication deficient but does
express the virally encoded superantigens (Sags). Sags
expression results in a depletion of specific T cell subsets.
These mice, when infected with exogenous MMTV, are
prone to the development of mammary gland tumors.
The group created MMTV-negative mice, which were
found to be protected from a replication-competent, exog-
enous MMTV, type B leukemogenic virus and Vibrio chol-
erae. Subsequently infected with MMTV, MMTV-null mice
lacked an immune response to the virus and lacked the
tumor development. Genetic analysis revealed that the
susceptibility to MMTV infection of endogenously
infected mice was a recessive feature and that a single
MMTV gene product was rendering these animals suscep-
tible to infection, implying a novel mechanism of resist-
ance to both viral and bacterial pathogens.
Another story on resistance to viral infection dealt with
HIV restriction in Old World monkeys by a cellular restric-
tion factor named TRIM5α. This molecule is a big hit in
HIV research, ever since the Sodroski group from Harvard
University published data from a primary rhesus monkey
lung fibroblasts cDNA library screen for the resistance to
HIV-1 infection [8]. Matt Stremlau gave us an insight on
how this restriction factor might work in order to block
the incoming virus at the post-entry step but pre-integra-
tion. Previously defined interaction of TRIM5α with theRetrovirology 2005, 2:72 http://www.retrovirology.com/content/2/1/72
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viral core served as a starting point to speculate that
TRIM5α could either stabilize the capsid core, cause rapid
disassembly of the core or target the capsid (CA) for pro-
teasomal degradation. All three outcomes could have an
impact on the very time-sensitive process of the reverse
transcription. From their work on in vitro assembled HIV
cores, representing highly ordered tubular structure of p24
CA hexamers [9], the group found that TRIM5α in its
functional trimeric form binds only to the core composed
out of CA hexamers, but does not bind to p24 CA mono-
mers. Since their data indicate that the proteasomal inhib-
itors did not recover the loss of the oligomeric into the
monomeric CA form, the group speculated that TRIM5α
most probably acts to rapidly disassemble the core and
that would impair the reverse transcription process, also
implying the species-specific blocking mechanism on the
conformational level.
On the other hand, Philippe Gallay from The Scripps
Research Institute showed recent data arguing that HIV CA
but not the matrix protein was being targeted for degrada-
tion, although other than through proteasomal pathway,
since proteasomal inhibitors did not fully rescue the
RhMTRIM5α mediated degradation of the HIV CA. This
group argued that TRIM5α restriction occurs at the level of
accelerated degradation of the core, possibly also affecting
the nuclear import of the preintegration complex.
Microscopy based approach to study the cellular localiza-
tion of TRIM5α in living cells came from Thomas Hope
group at Northwestern University. The audience had a
chance to see that both exogenous and endogenous
TRIM5α formed cytoplasmic bodies, but the proteins
were also found in the nuclei. The cytoplasmic bodies are
highly dynamic hollow structures and their formation is
speculated to be relevant in the TRIM5α function as a
restriction factor. The morphology of the bodies could be
altered with the proteasome inhibitor MG132, where the
smaller bodies merged to form bigger structures. The
group is currently investigating the effect of MG132 on the
TRIM5α restriction potency.
An interesting study came from Bruce Torbett's group,
where Christina Swan presented work on the design of
HIV based vectors for gene therapy in human stem and T
cells based on the HIV tropism. However, since monkeys
would be the animal model for the vector design trials, the
problem of the intrinsic cellular restriction of incoming
HIV virions by the RhTRIM5α arose. In order to overcome
this restriction problem, the group decided to test numer-
ous HIV CA mutants and found that incorporation of the
naturally occurring four amino acid substitutions in the
CypA binding site of HIV Gag/Pol allowed for the restric-
tion escape and therefore higher transduction efficiencies
in primary human and monkey cell lines. These muta-
tions allowed independence of CypA in human cells and
loss of TRIM5α recognition because of the lack of CypA
incorporation into the virions in monkey cells.
Another way to block HIV infection besides engaging the
endogenous restriction machinery is to test the potential
antimicrobial compounds. Christopher Aiken from Van-
derbilt University introduced us to the HIV-1 maturation
inhibitor 3-O-{3',3'- dimethylsuccinyl}-betulinic acid
(DSB). DSB specifically inhibits HIV replication by delay-
ing the last step in the Gag maturation: the release of the
spacer peptide SP1 from the C-terminus of CA. However,
the inhibitory effect was not due to the protease (PR) inhi-
bition, since PR inactivation stabilized the DSB:CA com-
plex. The escape mutants in CA-SP1 junction were not
incorporating DSB and were now rendered resistant to it.
Moreover, Aiken showed data supporting the hypothesis
that DSB binds to a pocket formed by Gag oligomeriza-
tion, an interaction that sterically inhibits PR from bind-
ing [10]. The compound had to be present at the time of
the viral assembly in order to inhibit the viral replication
in a dose-dependant manner and was also shown to be a
weak fusion inhibitor.
The session on viral uncoating and budding was con-
cluded by the talk from Wesley Sundquist's group from
University of Utah. Their research focuses on structural
proteomics to understand the process of ubiquitinated
Gag recognition by the cellular sorting machinery through
endosomal sorting complexes required for transport
(ESCRT I-III), utilization of multivesicular bodies forma-
tion and the energy of ATP hydrolysis in the viral protein
sorting, assembly and budding. Melissa Stuchell-Brereton
presented recently published data on the latest structural
analysis of one of the players in this cellular machinery
that mediates recycling of the sorting apparatus from the
cargo, namely VPS4A AAA ATPase [11]. Stuchell-Brereton
described the novel three-dimensional structure of VPS4A
C-terminal helix and N-terminal fragment: a microtubule
interacting and transport domain (MIT). Data suggested
that the VPS4A MIT domain directly binds the C-terminus
of one of the ESCRT-III proteins, allowing the formation
of the ring structure, where VPS4 proteins may serve to
unfold, translocate and therefore recycle the members of
ESCRT-III family through the ring pore, indirectly facilitat-
ing HIV budding.
HIV Inhibition and Activation
David Margolis of the University of North Carolina at
Chapel Hill gave the keynote lecture of this session, recap-
ping work his lab has completed in depleting latent HIV
infection from resting CD4+ cells [12]. In the twenty years
since the discovery of HIV, several anti-retroviral therapies
have been attempted, many of which have terrible side
effects and are not well tolerated by patients. In addition,Retrovirology 2005, 2:72 http://www.retrovirology.com/content/2/1/72
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while viremia may be reduced during treatment, viral load
increases significantly once therapy is stopped. A major
obstacle to eradication of HIV infection is the persistence
of a latent viral reservoir within resting CD4+ cells. There-
fore, stimulating HIV expression from these resting CD4+
T cells would allow the immune system to recognize
infected cells and target the infection more efficiently.
Histone deacetylase 1 (HDAC1) is instrumental in main-
taining latency of integrated HIV, thus inhibitors of
HDAC1, such as the FDA-approved valproic acid (VPA),
may assist in expression of HIV from resting CD4+ cells. To
examine this hypothesis, Margolis' group supplemented
the treatment of four patients with therapeutic doses of
VPA. Infection of CD4+ cells decreased in all patients, with
three exceeding expectations. While considerable work
still remains to be completed, these results suggest VPA
may be a promising addition to HIV treatment.
The subsequent two talks examined the participation of
certain transcription factors in HIV expression. Jonathan
Karn from Case School of Medicine and his lab have
recently completed research studying the molecular
mechanisms of NF-κB and other transcription factors in
expression of integrated HIV. To conduct these studies,
they created a population of T cells that possessed stably
integrated proviral HIV genomes that encoded GFP. The
group used these cells to evaluate the activation of HIV
transcription, as they turn green following treatment with
TNF-α. Additionally, they were able to evaluate the distri-
bution of RNA polymerase (RNA pol) II along HIV LTR as
well as the kinetics of proviral activation following recruit-
ment of TFIIH and NF-κB to the promoter and provirus by
using chromatin immunoprecipitation (ChIP). These
studies revealed recruitment of NF-κB coincided with an
accumulation of RNA pol and TFIIH within the nucleus.
Interestingly, induction of transcription was found to be
transient, with levels of RNA pol, TFIIH, and NF-κB
returning to pretreatment levels within 90 minutes fol-
lowing activation, only to increase in a second cycle of
induction 3 to 5 hours later. Although the mechanism is
more complicated, T cells stimulated though the T cell
receptor CD3 experienced a similar trend. Initially, NFAT
was observed to be selectively mobilized, only to be
replaced by NF-κB within 30 minutes. These observations
suggest the induction of HIV transcription is a multifacto-
rial process that is cyclical in nature, not the sustained
event as previously supposed.
Andrew Rice from Baylor College of Medicine presented
his lab's investigation of the role of 7SK small nuclear
RNA (7SK) in P-TEFb function and, in doing so, chal-
lenged the previously described model for these proteins
in HIV expression [13]. P-TEFb is a RNA pol II transcrip-
tion factor that is composed of Cdk9 and cyclin T1, T2 or
K. The HIV Tat protein targets the Cdk9/cyclin T1 P-TEFb
to activate transcription of the viral genome. Much of this
P-TEFb is complexed to 7SK and HEXIM proteins, how-
ever, and this complex has been demonstrated to have
decreased kinase activity in vitro. Rice and colleagues
examined 7SK and HEXIM in primary cells and found
expression of these proteins positively correlated with the
activation state of the cells. Additionally, there was no
observed difference in expression of endogenous genes or
integrated HIV provirus when siRNA was used to deplete
7SK, although expression of reporter plasmids increased.
Another interesting observation was that apoptosis was
induced within 72 hours in 7SK depleted cells. This group
postulates these findings indicate 7SK plays a significant
role in P-TEFb function, one that merits further investiga-
tion.
Wendong Yu from Baylor College of Medicine at Hou-
ston, Texas discussed the function of cyclin T1 in Mono-
Mac-6 (MM6) cells as a model for primary monocytes-to-
macrophages differentiation. The work was based on the
observation that the differentiation of monocytes into
macrophages (MΦs) is followed by the increasing levels of
CycT1, which together with CDK9 constitutes for P-TEFb,
a factor necessary for Tat-induced transcriptional activa-
tion. In the early MΦs, both CycT1 and Tat levels were ele-
vated, but there was a significant loss of CycT1 expression
in late MΦs that could be restored with PMA, IFNγ or LPS
induced signaling. Indeed, when CycT1 was knocked out
in MM6 cells using a shRNA approach, microarray analy-
sis revealed downregulation of ~13% genes, where ~11%
genes were PMA-inducible ones. This data emphasized
the role of the CycT1 induction in MΦ differentiation and
upregulation of ~11% genes.
Mary Lewinski from Bushman's group gave us an insight
into the integration target specificity of HIV and MLV [14].
After extensive integration site cloning, mapping to the
genome and considerable statistical analyses, the group
concluded that the chromosomal environment influences
the expression of integrated sequences and that different
retroviruses show disparate preferences for integration of
their genome into the host chromosomes. To understand
which viral proteins orchestrate the choice for the integra-
tion location within the host genome, numerous chimeric
viruses between MLV and HIV were tested for the prefer-
ential sites for integration. The interesting conclusion was
that not one, but a pair of genes, Gag and integrase,
worked synergistically to determine the integration site
specificity.
The last two talks in this session were reserved for poten-
tial antiviral agents. The talk from Vanderbilt University
by Derya Unutmaz focused on VacA toxin, produced by
bacterium Helicobacter pylori. The group observed that the
infectivity levels in primary activated T cells, normally sus-Retrovirology 2005, 2:72 http://www.retrovirology.com/content/2/1/72
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ceptible to HIV infection, dropped almost 100% when
pre-treated with VacA. The block was determined to be
post-reverse transcription, but pre-integration, possibly at
the level of nuclear membrane. VacA was not affecting
TCR signaling, but was shown to downregulate IL-2 pro-
duction and secretion, leading to abrogation of prolifera-
tion, an effect similar to rapamycin. However, the group is
still investigating the host target(s) of this toxin.
Roland Wolkowicz from Stanford University explained
the method for screening of relatively large number of
random peptide libraries for resistance to HIV infection.
The rationale behind random screening for antiviral com-
pounds was found in a possible steric block between the
viral and host proteins involved in HIV lifecycle, that
could lead to the gain of resistance of the cells transduced
with retroviral vector carrying the peptide library formed
in silico. Using this approach, Wolkowicz and his collabo-
rators confirmed the positive role of the signalosome and
Casein Kinase II in HIV lifecycle, as a randomly chosen
peptide could interact with these proteins and block the
HIV replication.
VPU and HIV Transinfection
The first two talks in this session explored the function of
HIV accessory protein Vpu. While Vpu has been well char-
acterized to enhance virus release, the mechanism by
which Vpu accomplishes this has remained unknown.
Edward Stephens from the University of Kansas and his
lab investigated the role of the transmembrane (TM)
domain of Vpu as well as its ion channel properties by
exchanging this domain for the M2 protein domain from
influenza A [15]. While this exchange had little effect on
replication, viral maturation or pathogenicity, the mutant
virus now became susceptible to antiviral drugs that spe-
cifically targeted the M2 ion channel, namely amantadine
and rimantadine. Studies of the M2 protein mapped the
ion channel's function to its HxxxW motif. By replacing a
single alanine residue with histidine, this group was able
to construct a Vpu protein, which possessed this HxxxW
motif within its TM domain. This alteration was sufficient
to render HIV susceptible to rimantadine. These studies
suggest the Vpu ion channel may be an effective target for
anti HIV therapeutics.
Beth Noble from Paula Cannon's lab at Childrens Hospi-
tal Los Angeles presented work on the involvement of the
cytoplasmic tail of Vpu in to enhancing viral release.
Microscopic analysis revealed Vpu in a mutant HeLa cell
line (HeLa-T17) was aberrantly concentrated in the peri-
nuclear region; a phenotype which the group hypothe-
sized was the result of improper trafficking with adaptor
protein 3 (AP-3). AP-3 depletion by siRNA and alteration
of a specific motif within the cytoplasmic tail of Vpu seem
to support this hypothesis. Together, these studies have
identified two specific regions of Vpu that affect viral
release, namely the transmembrane ion channel and the
AP-3 interacting cytoplasmic tail.
Sheila Barry from Thomas Hope's lab at Northwestern
University began the discussion of HIV transinfection, by
describing recent studies investigating the role of Langer-
hans cells (LCs) in mediating transinfection. Previously,
considerable efforts have been invested in studying the
effect of DC-SIGN-expressing dendritic cells (DCs) on
HIV infection. Such DCs are confined to deep tissue lay-
ers, where they may not readily encounter HIV. In con-
trast, Langerhans cells reside in surface epithelial tissue,
and can send dendritic processes across intact tight junc-
tions to sample pathogens prior to host infection. Using a
luciferase reporter assay, this group demonstrated that
LCs exposed to X4-tropic virus could enhance viral infec-
tivity in a manner similar to mature DCs. In addition, flu-
orescent microscopy revealed GFP-labeled HIV was found
in CD1a+ compartments within activated LCs and this
overlap continued in recipient T cells. These results sug-
gest LCs can enhance HIV infectivity without becoming
infected themselves, and viral delivery potentially takes
place through an infectious synapse resulting in delivery
of both virus and LC specific proteins to target cells.
In his second talk of the conference, Derya Unutmaz pre-
sented evidence that antimicrobial peptides derived from
amphibian skin (A-AMPs) inhibit both HIV infection and
viral transfer between DCs and T cells [16]. Using GFP
labeled virus, they observed three A-AMPs, caerin 1.1,
caerin 1.9 and maculatin 1.1, could inhibit HIV infection
of target cells within minutes of exposure at concentra-
tions that did not affect cell viability. Further, caerin 1.9
could inhibit both HIV and MLV regardless of Env, while
it had no effect on the non-enveloped reovirus. As DCs
have previously been shown to mediate HIV transinfec-
tion by internalizing the virus and protecting viral parti-
cles from intracellular degradation, Unutmaz and
colleagues considered A-AMPs might affect viral transfer
from DCs to T cells. Addition of A-AMPs to HIV-pulsed
DCs up to 8 hours post virus exposure was found to
inhibit DC-mediated transinfection of T cells, however
pretreating DCs with peptides prior to virus exposure had
no effect on viral infectivity. A-AMPs were either neutral-
izing virus at the cell surface or trafficking to the same
intracellular compartment as HIV and inactivating virus
there. Through fluorescent microscopy, the group
observed A-AMPs neutralized GFP labeled HIV and were
confined to the surface of DCs. This suggests internalized
virus may be continually cycling to the surface.
Retrovirus Pathogenesis
Maribeth Eiden from the NIH discussed her lab's efforts in
tracking the evolution of gammaretroviruses in gibbonRetrovirology 2005, 2:72 http://www.retrovirology.com/content/2/1/72
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apes and koalas. Gibbon ape leukemia virus (GALV) was
originally identified in captive gibbon apes in the 1970s.
Recently, koala retrovirus (KoRV) was isolated from cap-
tive koalas. Interestingly, KoRV shares a 78% nucleotide
identity with GALV, despite the fact that GALV is an exog-
enous retrovirus affecting gibbon apes while KoRV is
endogenously found in koalas. This suggests GALV and
KoRV probably originated from a common ancestor, with
KoRV diverging at an earlier time point than GALV. One
potential source could be an infectious murine gammaret-
rovirus, as elements related to the envelope genes of GALV
and KoRV were found in the genomes of several Asian
feral mice species. In an attempt to identify potential vec-
tors for transmission between koalas in Australia and gib-
bon apes in Thailand, Eiden et al found both GALV and
KoRV were able to infect mosquito cells, thus establishing
the possibility that insects could have acted as an infec-
tious intermediate.
Stacey Hull from Hung Fan's lab at the University of Cali-
fornia-Irvine closed the conference by presenting her work
on the cytoplasmic tail of Jaagsiekte sheep retrovirus
(JSRV) Env mediating transformation. They found JSRV-
mediated transformation transpired by signaling through
either the PI-3K-Akt-mTOR or the Ras-MEK-MAPK path-
ways, transformation was negatively regulated by p38 sig-
naling, and phosphatidylinositol 3-kinase (PI3-K)
binding site (YxxM) found in the cytoplasmic tail was nec-
essary for transformation [17]. By conducting an alanine
scan across the full length of the cytoplasmic tail, they cre-
ated mutant Env proteins that affected transformation
efficiency. Interestingly, one mutant increased JSRV trans-
formation efficiency, although it was unaffected by inhib-
itors of the mTOR or Ras pathways, implying signaling in
this mutant may be taking place through another
unknown pathway. To further investigate the importance
of the PI3-K binding motif, Hull exchanged the methio-
nine residue either to aspartic acid, lysine, serine, or iso-
leucine. Interestingly, the isoleucine mutant, which has
essentially been transformed into the binding motif for
Src, had a greater transformation efficiency as compared
to wildtype, thus suggesting Src may play some role in
JSRV transformation.
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